Skip to content

Study · Animal study (in vivo) · dog · 1987

12 results

Similar dose responsiveness of hepatic glycogenolysis and gluconeogenesis to glucagon in vivo.

Stevenson RW, Steiner KE, Davis MA, Hendrick GK, Williams PE, Lacy WW, Brown L, Donahue P, Lacy DB, Cherrington AD

Diabetes1 Mar 1987Cited by 53 (Europe PMC)

PMID2879758 (opens in a new tab)DOI10.2337/diab.36.3.382 (opens in a new tab)PepBankPUB-02879758
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, eightfold glucagon infusion increased initial glucose production by 6.5 +/- 0.6 mg X kg-1 X min-1.

    In plain wordsIn dogs, eightfold glucagon infusion increased initial glucose production.

    Peptide
    Glucagon
    Outcome
    IncreaseInitial glucose production at 8-fold infusion
    Study

    dogn = 6

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    8-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    Glucose production increase
    6.5 mg X kg-1 X min-1
    15-30 min
    Reported variability
    0.6 mg X kg-1 X min-1
    8-fold infusion
    Plasma glucagon increase
    402 pg/ml
    8-fold infusion
    Reported variability
    28 pg/ml
    8-fold infusion

    Source sentences

    Summary
    Increases in plasma glucagon of 53 +/- 8, 199 +/- 48, 402 +/- 28, and 697 +/- 149 pg/ml resulted in initial (15-30 min) increases in GP of 1.1 +/- 0.4 (N = 4), 4.9 +/- 0.5 (N = 4), 6.5 +/- 0.6 (N = 6), and 7.7 +/- 1.4 (N = 4) mg X kg-1 X min-1, respectively;
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, eightfold glucagon infusion increased gluconeogenesis by 161 +/- 25% at approximately 3 h.

    In plain wordsIn dogs, eightfold glucagon infusion increased new glucose production.

    Peptide
    Glucagon
    Outcome
    IncreaseGluconeogenesis at 8-fold infusion
    Study

    dogn = 6

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    8-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    GNG increase
    161%
    approximately 3 h
    Reported variability
    25%
    8-fold infusion

    Source sentences

    Summary
    increases in GNG (approximately 3 h) of 48 +/- 19, 151 +/- 50, 161 +/- 25, and 157 +/- 7%, respectively;
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, eightfold glucagon infusion increased hepatic fractional alanine extraction by 0.42 +/- 0.04 at 3 h.

    In plain wordsIn dogs, eightfold glucagon infusion increased the fraction of alanine extracted by the liver.

    Peptide
    Glucagon
    Outcome
    IncreaseHepatic fractional alanine extraction at 8-fold infusion
    Study

    dogn = 6

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    8-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    FEA increase
    0.42 fraction
    3 h
    Reported variability
    0.04 fraction
    8-fold infusion

    Source sentences

    Summary
    and increases in FEA (3 h) of 0.14 +/- 0.07, 0.37 +/- 0.05, 0.42 +/- 0.04, and 0.40 +/- 0.17, respectively.
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, doubling glucagon infusion increased initial glucose production by 1.1 +/- 0.4 mg X kg-1 X min-1.

    In plain wordsIn dogs, doubling glucagon infusion increased initial glucose production.

    Peptide
    Glucagon
    Outcome
    IncreaseInitial glucose production at 2-fold infusion
    Study

    dogn = 4

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    Glucose production increase
    1.1 mg X kg-1 X min-1
    15-30 min
    Reported variability
    0.4 mg X kg-1 X min-1
    2-fold infusion
    Plasma glucagon increase
    53 pg/ml
    2-fold infusion
    Reported variability
    8 pg/ml
    2-fold infusion

    Source sentences

    Summary
    Increases in plasma glucagon of 53 +/- 8, 199 +/- 48, 402 +/- 28, and 697 +/- 149 pg/ml resulted in initial (15-30 min) increases in GP of 1.1 +/- 0.4 (N = 4), 4.9 +/- 0.5 (N = 4), 6.5 +/- 0.6 (N = 6), and 7.7 +/- 1.4 (N = 4) mg X kg-1 X min-1, respectively;
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, fourfold glucagon infusion increased initial glucose production by 4.9 +/- 0.5 mg X kg-1 X min-1.

    In plain wordsIn dogs, fourfold glucagon infusion increased initial glucose production.

    Peptide
    Glucagon
    Outcome
    IncreaseInitial glucose production at 4-fold infusion
    Study

    dogn = 4

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    4-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    Glucose production increase
    4.9 mg X kg-1 X min-1
    15-30 min
    Reported variability
    0.5 mg X kg-1 X min-1
    4-fold infusion
    Plasma glucagon increase
    199 pg/ml
    4-fold infusion
    Reported variability
    48 pg/ml
    4-fold infusion

    Source sentences

    Summary
    Increases in plasma glucagon of 53 +/- 8, 199 +/- 48, 402 +/- 28, and 697 +/- 149 pg/ml resulted in initial (15-30 min) increases in GP of 1.1 +/- 0.4 (N = 4), 4.9 +/- 0.5 (N = 4), 6.5 +/- 0.6 (N = 6), and 7.7 +/- 1.4 (N = 4) mg X kg-1 X min-1, respectively;
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, twelvefold glucagon infusion increased initial glucose production by 7.7 +/- 1.4 mg X kg-1 X min-1.

    In plain wordsIn dogs, twelvefold glucagon infusion increased initial glucose production.

    Peptide
    Glucagon
    Outcome
    IncreaseInitial glucose production at 12-fold infusion
    Study

    dogn = 4

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    12-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    Glucose production increase
    7.7 mg X kg-1 X min-1
    15-30 min
    Reported variability
    1.4 mg X kg-1 X min-1
    12-fold infusion
    Plasma glucagon increase
    697 pg/ml
    12-fold infusion
    Reported variability
    149 pg/ml
    12-fold infusion

    Source sentences

    Summary
    Increases in plasma glucagon of 53 +/- 8, 199 +/- 48, 402 +/- 28, and 697 +/- 149 pg/ml resulted in initial (15-30 min) increases in GP of 1.1 +/- 0.4 (N = 4), 4.9 +/- 0.5 (N = 4), 6.5 +/- 0.6 (N = 6), and 7.7 +/- 1.4 (N = 4) mg X kg-1 X min-1, respectively;
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, doubling glucagon infusion increased gluconeogenesis by 48 +/- 19% at approximately 3 h.

    In plain wordsIn dogs, doubling glucagon infusion increased new glucose production.

    Peptide
    Glucagon
    Outcome
    IncreaseGluconeogenesis at 2-fold infusion
    Study

    dogn = 4

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    GNG increase
    48%
    approximately 3 h
    Reported variability
    19%
    2-fold infusion

    Source sentences

    Summary
    increases in GNG (approximately 3 h) of 48 +/- 19, 151 +/- 50, 161 +/- 25, and 157 +/- 7%, respectively;
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, fourfold glucagon infusion increased gluconeogenesis by 151 +/- 50% at approximately 3 h.

    In plain wordsIn dogs, fourfold glucagon infusion increased new glucose production.

    Peptide
    Glucagon
    Outcome
    IncreaseGluconeogenesis at 4-fold infusion
    Study

    dogn = 4

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    4-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    GNG increase
    151%
    approximately 3 h
    Reported variability
    50%
    4-fold infusion

    Source sentences

    Summary
    increases in GNG (approximately 3 h) of 48 +/- 19, 151 +/- 50, 161 +/- 25, and 157 +/- 7%, respectively;
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, twelvefold glucagon infusion increased gluconeogenesis by 157 +/- 7% at approximately 3 h.

    In plain wordsIn dogs, twelvefold glucagon infusion increased new glucose production.

    Peptide
    Glucagon
    Outcome
    IncreaseGluconeogenesis at 12-fold infusion
    Study

    dogn = 4

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    12-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    GNG increase
    157%
    approximately 3 h
    Reported variability
    7%
    12-fold infusion

    Source sentences

    Summary
    increases in GNG (approximately 3 h) of 48 +/- 19, 151 +/- 50, 161 +/- 25, and 157 +/- 7%, respectively;
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, doubling glucagon infusion increased hepatic fractional alanine extraction by 0.14 +/- 0.07 at 3 h.

    In plain wordsIn dogs, doubling glucagon infusion increased the fraction of alanine extracted by the liver.

    Peptide
    Glucagon
    Outcome
    IncreaseHepatic fractional alanine extraction at 2-fold infusion
    Study

    dogn = 4

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    FEA increase
    0.14 fraction
    3 h
    Reported variability
    0.07 fraction
    2-fold infusion

    Source sentences

    Summary
    and increases in FEA (3 h) of 0.14 +/- 0.07, 0.37 +/- 0.05, 0.42 +/- 0.04, and 0.40 +/- 0.17, respectively.
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, fourfold glucagon infusion increased hepatic fractional alanine extraction by 0.37 +/- 0.05 at 3 h.

    In plain wordsIn dogs, fourfold glucagon infusion increased the fraction of alanine extracted by the liver.

    Peptide
    Glucagon
    Outcome
    IncreaseHepatic fractional alanine extraction at 4-fold infusion
    Study

    dogn = 4

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    4-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    FEA increase
    0.37 fraction
    3 h
    Reported variability
    0.05 fraction
    4-fold infusion

    Source sentences

    Summary
    and increases in FEA (3 h) of 0.14 +/- 0.07, 0.37 +/- 0.05, 0.42 +/- 0.04, and 0.40 +/- 0.17, respectively.
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In fasted dogs, twelvefold glucagon infusion increased hepatic fractional alanine extraction by 0.40 +/- 0.17 at 3 h.

    In plain wordsIn dogs, twelvefold glucagon infusion increased the fraction of alanine extracted by the liver.

    Peptide
    Glucagon
    Outcome
    IncreaseHepatic fractional alanine extraction at 12-fold infusion
    Study

    dogn = 4

    Conscious overnight-fasted dogs with basal insulin replacement and somatostatin suppression
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    12-fold basal infusion of 0.65 ng X kg-1 X min-1 · intraportal infusion · 3 hAs given in this study (dog).

    Measurements

    FEA increase
    0.4 fraction
    3 h
    Reported variability
    0.17 fraction
    12-fold infusion

    Source sentences

    Summary
    and increases in FEA (3 h) of 0.14 +/- 0.07, 0.37 +/- 0.05, 0.42 +/- 0.04, and 0.40 +/- 0.17, respectively.
    2 context sentences
    Summary · context
    This study was undertaken to determine whether the dose-dependent effect of glucagon on gluconeogenesis parallels its effect on hepatic glycogenolysis in conscious overnight-fasted dogs.
    Summary · context
    The glucagon infusion was then increased 2-, 4-, 8-, or 12-fold for 3 h, whereas the rate of insulin infusion was left unchanged.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.